Novartis Highlights Pipeline Growth, New Data Across Diabetes and CV Programs
-
Focus on early pipeline expansion through core research and new technology
-
Phase 1 data for novel GLP-1 and amylin co-agonist amycretin
-
Scaling manufacturing capacity to increase patient reach
-
Growth potential for semaglutide; data from kidney outcomes trial FLOW
-
Expanding pipeline in CV; additional data from SELECT obesity trial